Therapeutics News and Research

RSS

Personalized exercise testing may be more effective for fat loss

The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.

11 Aug 2023

Brain development linked to the emergence of autism spectrum disorder

Two distinct neurodevelopmental abnormalities that arise just weeks after the start of brain development have been associated with the emergence of autism spectrum disorder, according to a new Yale-led study in which researchers developed brain organoids from the stem cells of boys diagnosed with the disorder.

10 Aug 2023

Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy

Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial.

10 Aug 2023

Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

A new study of mice and lab-grown human colon "organoids" indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.

10 Aug 2023

Scientists develop novel animal model of neurobrucellosis

Neurobrucellosis is a severe long-term complication of brucellosis, one of the most common bacterial zoonotic diseases.

10 Aug 2023

MaxCyte signs strategic platform license with Lyell Immunopharma

From MaxCyte, Inc. 10 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

From MaxCyte, Inc. 10 Aug 2023

Stem cell transplants may be a promising therapeutic against Alzheimer's, study shows

In the ongoing search for a cure for Alzheimer's disease, a burgeoning branch of medicine is bringing new hope. Stem cell therapies are already being used to treat various cancers and disorders of the blood and immune system.

9 Aug 2023

Duke researchers develop potent antibiotic against drug-resistant superbugs

A scientific journey decades in the making at Duke University has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, the culprits in many urinary tract infections (UTIs).

9 Aug 2023

Immunotherapy after stem cell transplantation effectively combats certain childhood nerve tumors

Scientists at St. Anna Children's Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children.

9 Aug 2023

Researchers design a probiotic to suppress autoimmunity in the brain

Brigham researchers are working on a new approach to target autoimmunity in the brain leverages designer bacteria to make treatment safer and more effective.

9 Aug 2023

Nanotechnology's triple threat: Advancing precision cancer treatment

The design of tumor tissue-, cell-, and organelle-targeted cancer nanomedicines.

9 Aug 2023

Nationwide Children's Hospital pioneers new gene therapy for Duchenne muscular dystrophy

In a landmark moment for the Abigail Wexner Research Institute at Nationwide Children's, a 5-year-old from Bellefontaine, Ohio, received the first dose of a recently approved gene therapy for Duchenne muscular dystrophy at Nationwide Children's Hospital, where the therapy was invented and initially tested.

8 Aug 2023

Mitochondrial protein structure activates cell's integrated stress response

Often referred to as the "powerhouses of the cell," mitochondria are well known for their role as energy suppliers, but these organelles are also critical for maintaining our overall health.

8 Aug 2023

New antibody shows promise in reversing carfentanil overdoses

An antibody in single-chain fragment variable (scFv) format that binds to the powerful opioid carfentanil was shown to reverse signs of carfentanil overdose in preclinical tests conducted by scientists at Scripps Research.

7 Aug 2023

Phage therapy shows promise in treating tough Pseudomonas aeruginosa infections

A new international study conducted by the Israeli Phage Therapy Center (IPTC) led by Prof. Ran Nir-Paz at Hadassah Hebrew University Medical Center and Prof. Ronen Hazan of the Faculty of Dental Medicine at The Hebrew University of Jerusalem, using phage PASA16 on compassionate basis to treat tough Pseudomonas aeruginosa infections, has shown promising results with an 86.6% success rate.

7 Aug 2023

UKHSA unveils world-leading Vaccine Development and Evaluation Centre

The UK Health Security Agency (UKHSA) has today unveiled its world-leading Vaccine Development and Evaluation Centre (VDEC), which is building on its pandemic legacy and helping develop life-saving new vaccines for the UK and worldwide.

7 Aug 2023

Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, today announced it has received notification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that the Company is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme, and is, therefore, able to offer GLP compliant hERG ion channel screening services to the global life sciences community.

From Metrion Biosciences Limited 7 Aug 2023

Machine learning in neurodegenerative disease research: a growing trend

Scientists explore the utility of machine learning methods in the field of neurodegenerative disease diagnosis, prognosis, and treatment effect prediction.

4 Aug 2023